articleNature MedicineSep 7, 2020GREEN OA

Avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma: biomarker analysis of the phase 3 JAVELIN Renal 101 trial

RJRobert J. MotzerPBPaul B. RobbinsTPThomas PowlesLALaurence AlbigèsJBJohn B.A.G. Haanen

Memorial Sloan Kettering Cancer Center · Pfizer (United States) · +18 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

515
total citations
FWCI
39.94
Percentile
100%
References
46
Citations per year

Authors

23

Topics & keywords

Topics
Keywords
  • Axitinib
  • Sunitinib
  • Avelumab
  • Renal cell carcinoma
  • Medicine
  • Biomarker
  • Oncology
  • Internal medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.

Funding